News
Asianet Newsable on MSN19m
Why Retail Investors Are Turning Sharply Bullish On Apellis Pharmaceuticals
The FDA approved Apellis’ drug Empaveli for two rare kidney diseases, following strong results from a Phase 3 trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback